[1]
|
Li, H., Guan, Y., Han, C., et al. (2021) The Pathogenesis, Models and Therapeutic Advances of Primary Biliary Cholan-gitis. Biomedicine & Pharmacotherapy, 140, Article ID: 111754. https://doi.org/10.1016/j.biopha.2021.111754
|
[2]
|
Galoosian, A., Hanlon, C., Zhang, J., et al. (2020) Clinical Up-dates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches. Journal of Clinical and Translational Hepatology, 8, 49-60.
https://doi.org/10.14218/JCTH.2019.00049
|
[3]
|
Zeng, N., Duan, W., Chen, S., et al. (2019) Epidemiology and Clinical Course of Primary Biliary Cholangitis in the Asia-Pacific Region: A Systematic Review and Meta-Analysis. Hepatology International, 13, 788-799.
https://doi.org/10.1007/s12072-019-09984-x
|
[4]
|
Gershwin, M.E., Selmi, C., Worman, H.J., et al. (2005) Risk Factors and Comorbidities in Primary Biliary Cirrhosis: A Controlled Interview-Based Study of 1032 Patients. Hepatol-ogy (Baltimore, Md), 42, 1194-1202.
https://doi.org/10.1002/hep.20907
|
[5]
|
Hitomi, Y., Aiba, Y., Kawai, Y., et al. (2021) Rs1944919 on Chromosome 11q23.1 and Its Effector Genes COLCA1/ COLCA2 Confer Susceptibility to Primary Biliary Cholangitis. Scientific Re-ports, 11, Article No. 4557.
https://doi.org/10.1038/s41598-021-84042-x
|
[6]
|
Cordell, H.J., Fryett, J.J., Ueno, K., et al. (2021) An Internation-al Genome-Wide Meta-Analysis of Primary Biliary Cholangitis: Novel Risk Loci and Candidate Drugs. Journal of Hepatology, 75, 572-581.
https://doi.org/10.1016/j.jhep.2021.04.055
|
[7]
|
Asselta, R., Paraboschi, E.M., Gerussi, A., et al. (2021) X Chro-mosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 160, 2483-2495.e26.
|
[8]
|
Hitomi, Y., Aiba, Y., Ueno, K., et al. (2022) Rs9459874 and Rs1012656 in CCR6/FGFR1OP Confer Susceptibility to Primary Biliary Cholangitis. Journal of Autoimmunity, 126, Article ID: 102775.
https://doi.org/10.1016/j.jaut.2021.102775
|
[9]
|
Qiu, F., Tang, R., Zuo, X., et al. (2017) A Genome-Wide Associa-tion Study Identifies Six Novel Risk Loci for Primary Biliary Cholangitis. Nature Communications, 8, Article No. 14828.
|
[10]
|
Hitomi, Y. and Nakamura, M. (2023) The Genetics of Primary Biliary Cholangitis: A GWAS and Post-GWAS Update. Genes, 14, Article No. 405. https://doi.org/10.3390/genes14020405
|
[11]
|
Gulamhusein, A.F. and Hirschfield, G.M. (2020) Primary Biliary Cholangitis: Pathogenesis and Therapeutic Opportunities. Nature Reviews Gastroenterology & Hepatology, 17, 93-110. https://doi.org/10.1038/s41575-019-0226-7
|
[12]
|
Prieto, J., Banales, J.M. and Medina, J.F. (2021) Primary Biliary Cholangitis: Pathogenic Mechanisms. Current Opinion in Gastroenterol-ogy, 37, 91-98. https://doi.org/10.1097/MOG.0000000000000703
|
[13]
|
Lindor, K.D., Bowlus, C.L., Boyer, J., et al. (2022) Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liv-er Diseases. Hepatology (Baltimore, Md), 75, 1012-1013.
https://doi.org/10.1002/hep.32117
|
[14]
|
You, H., Ma, X., Efe, C., et al. (2022) APASL Clinical Practice Guidance: The Diagnosis and Management of Patients with Primary Biliary Cholangitis. Hepatology International, 16, 1-23. https://doi.org/10.1007/s12072-021-10276-6
|
[15]
|
Harms, M.H., Van Buuren, H.R., Corpechot, C., et al. (2019) Ursodeoxycholic Acid Therapy and Liver Transplant-Free Survival in Patients with Primary Biliary Cholangitis. Journal of Hepatology, 71, 357-365.
https://doi.org/10.1016/j.jhep.2019.04.001
|
[16]
|
Pedersen, M.R., Greenan, G., Arora, S., et al. (2021) Ursodeoxy-cholic Acid Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplantation: A Meta-Analysis. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 27, 866-875. https://doi.org/10.1002/lt.25935
|
[17]
|
Chapman, R.W. and Lynch, K.D. (2020) Obeticholic Acid—A New Therapy in PBC and NASH. British Medical Bulletin, 133, 95-104. https://doi.org/10.1093/bmb/ldaa006
|
[18]
|
Murillo Perez, C.F., Fisher, H., Hiu, S., et al. (2022) Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. Gastroenterology, 163, 1630-1642.e3.
|
[19]
|
Trauner, M., Nevens, F., Shiffman, M.L., et al. (2019) Long-Term Efficacy and Safety of Obeticholic Acid for Patients with Primary Biliary Cholangitis: 3-Year Results of an International Open-Label Extension Study. The Lancet Gastroenterology & Hepatolo-gy, 4, 445-453. https://doi.org/10.1016/S2468-1253(19)30094-9
|
[20]
|
Wang, K., Zhang, Y., Wang, G., et al. (2023) FXR Agonists for MASH Therapy: Lessons and Perspectives from Obeticholic Acid. Medicinal Research Reviews. https://doi.org/10.1002/med.21991
|
[21]
|
Liu, Y., Guo, G., Zheng, L., et al. (2023) Effectiveness of Fenofibrate in Treatment-Naive Patients with Primary Biliary Cholangitis: A Randomized Clinical Trial. The American Journal of Gas-troenterology, 118, 1973-1979.
https://doi.org/10.14309/ajg.0000000000002238
|
[22]
|
Honda, A., Tanaka, A., Kaneko, T., et al. (2019) Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients with Primary Biliary Cholangitis. Hepa-tology (Baltimore, Md), 70, 2035-2046.
https://doi.org/10.1002/hep.30552
|
[23]
|
Sorda, J.A., González Ballerga, E., Barreyro, F.J., et al. (2021) Bezafibrate Therapy in Primary Biliary Cholangitis Refractory to Ursodeoxycholic Acid: A Longitudinal Study of Paired Liver Biop-sies at 5 Years of Follow-Up. Alimentary Pharmacology & Therapeutics, 54, 1202-1212. https://doi.org/10.1111/apt.16618
|
[24]
|
Carrion, A.F., Lindor, K.D. and Levy, C. (2021) Safety of Fibrates in Cho-lestatic Liver Diseases. Liver International: Official Journal of the International Association for the Study of the Liver, 41, 1335-1343.
https://doi.org/10.1111/liv.14871
|
[25]
|
Schattenberg, J.M., Pares, A., Kowdley, K.V., et al. (2021) A Randomized Placebo-Controlled Trial of Elafibranor in Patients with Primary Biliary Cholangitis and Incomplete Response to UDCA. Journal of Hepatology, 74, 1344-1354.
https://doi.org/10.1016/j.jhep.2021.01.013
|
[26]
|
Bowlus, C.L., Galambos, M.R., Aspinall, R.J., et al. (2022) A Phase II, Randomized, Open-Label, 52-Week Study of Seladelpar in Patients with Primary Biliary Cholangitis. Journal of Hepatology, 77, 353-364.
https://doi.org/10.1016/j.jhep.2022.02.033
|
[27]
|
Rautiainen, H., Kärkkäinen, P., Karvonen, A.L., et al. (2005) Budesonide Combined with UDCA to Improve Liver Histology in Primary Biliary Cirrhosis: A Three-Year Randomized Trial. Hepatology (Baltimore, Md), 41, 747-752.
https://doi.org/10.1002/hep.20646
|
[28]
|
Hirschfield, G.M., Beuers, U., Kupcinskas, L., et al. (2021) A Place-bo-Controlled Randomised Trial of Budesonide for PBC Following an Insufficient Response to UDCA. Journal of Hepatology, 74, 321-329.
https://doi.org/10.1016/j.jhep.2020.09.011
|
[29]
|
Wang, Z.L., Song, K.M., Jin, R., et al. (2022) Combination Thera-py of Ursodeoxycholic Acid and Glucocorticoid and (or) Immunosuppressant in Patients with Primary Biliary Cholangi-tis: A Meta-Analysis. Medicine, 101, e28987.
https://doi.org/10.1097/MD.0000000000028987
|
[30]
|
Khanna, A., Jopson, L., Howel, D., et al. (2019) Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial. Hepatol-ogy (Baltimore, Md), 70, 1646-1657.
https://doi.org/10.1002/hep.30099
|
[31]
|
Levy, C., Kendrick, S., Bowlus, C.L., et al. (2023) GLIMMER: A Ran-domized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients with Pruritus. Clinical Gas-troenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 21, 1902-1912.e13.
https://doi.org/10.1016/j.cgh.2022.10.032
|
[32]
|
Hegade, V.S., Kendrick, S.F., Dobbins, R.L., et al. (2016) BAT117213: Ileal Bile Acid Transporter (IBAT) Inhibition as a Treatment for Pruritus in Primary Biliary Cirrhosis: Study Protocol for a Randomised Controlled Trial. BMC Gastroenterology, 16, Article No. 71. https://doi.org/10.1186/s12876-016-0481-9
|
[33]
|
杨入, 卢秉久. 卢秉久治疗原发性胆汁性肝硬化经验撷菁[J]. 中医药临床杂志, 2016, 28(11): 1556-1558.
https://doi.org/10.16448/J.Cjtcm.2016.0547
|
[34]
|
卢秉久. 中医药辨治自身免疫性肝病的优势与困境[J]. 中西医结合肝病杂志, 2019, 29(6): 481-482.
|
[35]
|
谭家鑫, 王灵台, 纪龙珊, 等. 王灵台教授运用调免方治疗原发性胆汁性胆管炎临床经验[J]. 时珍国医国药, 2022, 33(7): 1753-1755.
|
[36]
|
于盈盈, 吕文良. 吕文良教授从肝脾论治原发性胆汁性胆管炎的经验[J]. 中国医药导报, 2023, 20(5): 133-136+141. https://doi.org/10.20047/J.Issn1673-7210.2023.05.31
|
[37]
|
徐洪玲, 邢宇锋, 徐留斌, 等. 周大桥教授治疗原发性胆汁性胆管炎临床经验[J]. 中西医结合肝病杂志, 2023, 33(8): 747-749.
|
[38]
|
倪旭, 王宪波. 王宪波教授治疗原发性胆汁性肝硬化的经验[J]. 中西医结合肝病杂志, 2023, 33(7): 652-653+659.
|
[39]
|
许杰, 戚璐, 楼汪洲洋, 等. 程良斌教授治疗原发性胆汁性胆管炎的临床经验[J]. 中西医结合肝病杂志, 2020, 30(2): 157-158.
|
[40]
|
肖丽娟, 陈建杰, 王劲秋, 等. 陈建杰教授治疗原发性胆汁性胆管炎经验撷菁[J]. 中西医结合肝病杂志, 2023, 33(8): 750-752.
|
[41]
|
刘晔, 车念聪, 田甜, 等. 原发性胆汁性肝硬化中医证治探讨[J]. 北京中医药, 2018, 37(11): 1082-1083.
https://doi.org/10.16025/J.1674-1307.2018.11.023
|
[42]
|
王石中, 苏晓岚, 涂雨落, 等. 孙克伟教授辨治原发性胆汁性胆管炎经验[J]. 湖南中医药大学学报, 2022, 42(11): 1927-1931.
|
[43]
|
王宇新, 彭文婉, 黄锦桢, 等. 基于数据挖掘的中医药治疗原发性胆汁性胆管炎用药规律研究[J]. 中药新药与临床药理, 2022, 33(8): 1124-1130. https://doi.org/10.19378/J.Issn.1003-9783.2022.08.017
|
[44]
|
王怡群, 张玮, 叶敏超, 等. 中药复方联合熊去氧胆酸治疗原发性胆汁性胆管炎患者的临床研究[J]. 中西医结合肝病杂志, 2021, 31(5): 398-401.
|
[45]
|
董桂芬. 中药联合熊去氧胆酸治疗原发性胆汁性肝硬化疗效观察[J]. 山西中医, 2019, 35(8): 24-25.
|